tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RNXT Stock Latest News

RenovoRx’s PanTheR Registry Trial: A Promising Update for Investors
Company AnnouncementsRenovoRx’s PanTheR Registry Trial: A Promising Update for Investors
3d ago
RNXT
RenovoRx Reports Revenue Growth and Trial Progress
PremiumCompany Announcements
RenovoRx Reports Revenue Growth and Trial Progress
3d ago
RNXT
RenovoRx Reports Strong Q2 2025 Revenue Growth
PremiumCompany Announcements
RenovoRx Reports Strong Q2 2025 Revenue Growth
3d ago
8K
RNXT
Meet RenovoRx: Fly exclusive interview with CEO Shaun Bagai
PremiumThe Fly
Meet RenovoRx: Fly exclusive interview with CEO Shaun Bagai
11d ago
RNXT
Phase 3 TIGeR-PaC Trial progressing well, RenovoRx CEO says
PremiumThe Fly
Phase 3 TIGeR-PaC Trial progressing well, RenovoRx CEO says
11d ago
RNXT
RenovoRx CEO sees disconnect with Wall Street, believes shares undervalued
PremiumThe FlyRenovoRx CEO sees disconnect with Wall Street, believes shares undervalued
11d ago
RNXT
RenovoRx not far from driving revenue to cover cash burn, CEO says
Premium
The Fly
RenovoRx not far from driving revenue to cover cash burn, CEO says
11d ago
RNXT
RenovoRx expands commercialization for RenovoCath, announces leadership hire
Premium
The Fly
RenovoRx expands commercialization for RenovoCath, announces leadership hire
12d ago
RNXT
RenovoRx Stockholders Approve Key Proposals at Annual Meeting
PremiumCompany Announcements
RenovoRx Stockholders Approve Key Proposals at Annual Meeting
2M ago
8K
RNXT
RenovoRx price target raised to $11.50 from $11 at Ascendiant
PremiumThe Fly
RenovoRx price target raised to $11.50 from $11 at Ascendiant
2M ago
RNXT
RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook
PremiumRatings
RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook
3M ago
RNXT
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating
PremiumRatings
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating
3M ago
RNXT
RenovoRx Earnings Call: Positive Outlook Amid Growth
PremiumCompany AnnouncementsRenovoRx Earnings Call: Positive Outlook Amid Growth
3M ago
RNXT
RenovoRx Reports Promising Q1 2025 Financial Results
Premium
Company Announcements
RenovoRx Reports Promising Q1 2025 Financial Results
3M ago
RNXT
RenovoRx Reports Strong Q1 2025 Financial Results
Premium
Company Announcements
RenovoRx Reports Strong Q1 2025 Financial Results
3M ago
8K
RNXT
RenovoRx reports Q1 EPS (8c), consensus (8c)
PremiumThe Fly
RenovoRx reports Q1 EPS (8c), consensus (8c)
3M ago
RNXT
RenovoRx announces Johns Hopkins initiated for TIGeR-PaC Phase 3 trial
PremiumThe Fly
RenovoRx announces Johns Hopkins initiated for TIGeR-PaC Phase 3 trial
4M ago
RNXT
RenovoRx Reports Initial Revenue and Clinical Trial Progress
PremiumCompany Announcements
RenovoRx Reports Initial Revenue and Clinical Trial Progress
4M ago
RNXT
RenovoRx increases production of RenovoCath
PremiumThe Fly
RenovoRx increases production of RenovoCath
4M ago
RNXT
RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
PremiumRatingsRenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
5M ago
RNXT
RenovoRx Delays Yearly Report Filing
Premium
Company Announcements
RenovoRx Delays Yearly Report Filing
5M ago
RNXT
RenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity
Premium
Ratings
RenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity
5M ago
RNXT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >